For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, ...

Troy Cox, who served on Zymeworks’ Board since 2019, has stepped down.

The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: https://greenwichlifesciences.com/ The Company's recent prior events ...

Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Novartis plans to present its data at an upcoming medical congress and submit ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 ...

Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index ...

Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350) and CHF 600 million ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, ...

The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio’s ...

Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under ...

Patent Issuance: In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 by the U.S. Patent and Trademark Office, covering its SWAP™ technology for creating multi-specific Wnt surrogate molecules ...